Efficacy of type I thyroplasty after endoscopic cordectomy for early‐stage glottic cancer: Literature review

Bertelsen, Caitlin; Reder, Lindsay

doi:10.1002/lary.26877

Cited by 8 publications

(5 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding is in accordance with the current literature, which has found thyroplasty to be a safe and effective method for closing glottic gaps after extended or total cordectomy. [26][27][28] This study has several limitations. It is difficult to generalize these experiences to other institutions, given the variability in patient populations and surgeon experience.…”

Section: Discussionmentioning

confidence: 96%

See 1 more Smart Citation

Safety of Outpatient Type 1 Thyroplasty

et al. 2020

View full text Add to dashboard Cite

Objective: Type 1 thyroplasty is an established procedure for the treatment of vocal fold paralysis to improve voice and swallowing outcomes. At our institution, we commonly perform this procedure on an outpatient basis in medically stable patients. With this study, we assess the safety of outpatient thyroplasty by examining complication and readmission rates, need for revision surgery, and predictors of these outcome measures. Methods: We performed a retrospective review of patients undergoing outpatient type 1 thyroplasty for vocal fold paralysis between 2013 and 2018 at our institution. We documented the etiology of paralysis, comorbidities, and demographic data. Our primary outcome measures were complications, need for readmission, and need for revision surgery. Results: During the study period, 160 patients met our inclusion criteria. Mean age at time of surgery was 62.1 ± 13.9 years; there were 82 (51%) males and 78 (49%) females. Nine (5.6%) patients experienced major complications after surgery and 7 (4.4%) patients required unplanned readmission. Mean time to complication was 6.9 ± 9.7 days. There were no instances of postoperative airway compromise requiring intervention. There were no mortalities. Of those who underwent primary surgery, 22 (14%) patients required revision surgery. Conclusion: Given that complications tend to occur in a delayed fashion rather than in the acute postoperative period, same-day discharge seems reasonable as compared to overnight observation in medically stable patients undergoing type 1 thyroplasty. Level of Evidence: IV

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

Safety of Outpatient Type 1 Thyroplasty

et al. 2020

View full text Add to dashboard Cite

show abstract

“…A systematic review by Bertelsen et al found that medialization thyroplasty is a useful tool in enhancing voice after cordectomy [ 20 ]. Villaret and colleagues reported on voice outcomes following intra-operative autologous fat injections into the neocord after type III laser cordectomy.…”

Section: Discussionmentioning

confidence: 99%

“…When TLM is used to treat early glottic cancers, the size of the glottic gap is influenced by the amount of tissue resected for oncologic control. The degree of post-operative dysphonia correlates directly with the size of the glottic gap [ 20 ].…”

Section: Introductionmentioning

confidence: 99%

Injection laryngoplasty during transoral laser microsurgery for early glottic cancer: A randomized controlled trial

Afif

Rigby

Mackay

et al. 2022

Journal of Otolaryngology - Head & Neck Surgery

View full text Add to dashboard Cite

Background Transoral laser microsurgery is widely used for treating T1/T2 glottic cancers. Hyaluronic acid (HA) is commonly used in vocal cord augmentation. We investigated the impact of intra-operative injection laryngoplasty on voice outcomes in early glottic cancer. Methods Twenty patients were randomized to the treatment group receiving HA injection to the vocal cord contralateral to the lesion; or the control group, receiving no injection. Patients had a Voice Handicap Index-10 (VHI-10) questionnaire and a Maximum Phonation Time (MPT) measurement preoperatively and at 3, 12 and 24 months post-operatively. Mean change in VHI-10 and MPT, compared to baseline and between time points, were compared. Survival estimates were calculated. Results Mean VHI-10 scores improved over time amongst all patients. There were no changes in mean VHI-10 from pre-operative values to 3, 12 or 24 months post-operatively. There were no significant differences when comparing various timepoints between groups. There were no significant changes in MPT amongst the groups, or the time-points compared. Two-year overall survival was 91.7%; disease free survival was 80.9%; no difference in recurrence free survival was seen between the groups. Conclusion Subjective voice scores improved over time in both groups; there were no improvements in VHI-10 or MPT scores in the injection group, over control, at any time points. We saw no significant impact for intra-operative HA injection laryngoplasty on subjective or objective voice outcomes following surgery for early glottic cancers. Graphical abstract

show abstract

“…A novel endoscopic AA with IL was developed as a rapid, minimally invasive solution for UVFP (49). There were adverse events associated with thyroplasty, including hematoma, infection, and implant extrusion (50).…”

Section: Type I Thyroplasty and Aamentioning

confidence: 99%

A narrative review of current therapies in unilateral recurrent laryngeal nerve injury caused by thyroid surgery

Tian¹,

Pan²,

Chen³

et al. 2022

Gland Surg

View full text Add to dashboard Cite

Objective: To summarize and compare current common treatments in recurrent laryngeal nerve injury (RLNI). In addition, we introduced nerve tissue engineering technology in RLNI animal models. This review is a comprehensive summary of current therapies for unilateral RLNI.Background: RLNI is a common complication in thyroid surgery. Although preoperative imaging and intraoperative nerve monitoring are widely applied, some damage to nerves is still inevitable. Currently, advances in nerve repair and regeneration have been made, but relatively few studies have focused on RLNI.In this review, we summarized and compared current common treatments in RLNI. Methods:We searched the literature on PubMed and Web of Science, and chose studies about RLNI in thyroid surgery. Keywords included the following terms: "recurrent laryngeal nerve regeneration", "injection laryngoplasty", "type I thyroplasty", "arytenoid adduction", and "nerve tissue engineering technology". Only English language studies were included. In the section on nerve tissue engineering technology, we described the application in detail in the table below.Conclusions: Currently, the majority of treatments could obtain different effects to some extent, but there are still shortcomings that need to be overcome further overcome. Therefore, potential exploration such as nerve tissue engineering technology is worthy of attention.

show abstract

Efficacy of type I thyroplasty after endoscopic cordectomy for early‐stage glottic cancer: Literature review

Abstract: Optimizing voice after EC remains a clinical challenge. Our review suggests that thyroplasty is one potentially beneficial option in appropriately selected patients. More controlled studies are needed to assess efficacy of thyroplasty in this context. Laryngoscope, 128:690-696, 2018.

Cited by 8 publications

References 27 publications

Safety of Outpatient Type 1 Thyroplasty

Safety of Outpatient Type 1 Thyroplasty

Injection laryngoplasty during transoral laser microsurgery for early glottic cancer: A randomized controlled trial

A narrative review of current therapies in unilateral recurrent laryngeal nerve injury caused by thyroid surgery

Contact Info

Product

Resources

About